Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance | Synapse
September 22, 2022Open Access
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Key Points
Key points are not available for this paper at this time.
Abstract
Nct02092467.
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Cite This Study
Charles‐Schoeman et al. (Thu,) studied this question.